Literature DB >> 18941760

Faecal calprotectin in colonic diverticular disease: a case-control study.

Antonio Tursi1, Giovanni Brandimarte, Walter Elisei, Gian Marco Giorgetti, Cosimo Damiano Inchingolo, Fabio Aiello.   

Abstract

BACKGROUND AND AIMS: Information about faecal calprotectin (FC) in colonic diverticular disease (DD) are lacking. We assessed FC in colonic DD, comparing it with irritable bowel syndrome (IBS) patients and healthy controls. Moreover, we compared FC levels in different degrees of DD and assessed FC in symptomatic DD before and after treatment.
MATERIALS AND METHODS: Forty-eight consecutive patients with a new endoscopic diagnosis of DD (16 with asymptomatic diverticulosis, 16 with symptomatic uncomplicated DD, 16 with acute uncomplicated diverticulitis), 16 healthy controls, and 16 IBS patients were studied. FC was assessed by semi-quantitative method and compared with histological inflammation. Moreover, FC was reassessed in symptomatic DD after 8 weeks of treatment. RESULTS/
FINDINGS: FC was not increased in healthy controls and IBS patients. No difference was found between asymptomatic diverticulosis, healthy controls, and IBS patients (p = n.s.). We found higher FC values in acute uncomplicated diverticulitis (p < 0.0005) and in symptomatic uncomplicated DD (p < 0.005) than in healthy controls and in IBS patients. FC values correlated with inflammatory infiltrate (p < 0.0005). FC decreased after treatment to normal values both in acute uncomplicated diverticulitis (p < 0.0005) and in symptomatic uncomplicated DD (p < 0.005) after treatment. INTERPRETATIONS/
CONCLUSIONS: FC may be useful to detect colonic inflammation in DD and in distinguishing symptomatic DD from IBS, as well as in assessing response to therapy in DD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18941760     DOI: 10.1007/s00384-008-0595-9

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  26 in total

Review 1.  Diagnosis and treatment of diverticular disease: results of a consensus development conference. The Scientific Committee of the European Association for Endoscopic Surgery.

Authors:  L Köhler; S Sauerland; E Neugebauer
Journal:  Surg Endosc       Date:  1999-04       Impact factor: 4.584

2.  Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study.

Authors:  Antonio Tursi; Giovanni Brandimarte; Gian Marco Giorgetti; Walter Elisei
Journal:  J Clin Gastroenterol       Date:  2006-04       Impact factor: 3.062

3.  Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study.

Authors:  A G Røseth; M K Fagerhol; E Aadland; H Schjønsby
Journal:  Scand J Gastroenterol       Date:  1992-09       Impact factor: 2.423

Review 4.  Review article: biological activity markers in inflammatory bowel disease.

Authors:  D Desai; W A Faubion; W J Sandborn
Journal:  Aliment Pharmacol Ther       Date:  2007-01-08       Impact factor: 8.171

5.  Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.

Authors:  Jost Langhorst; Sigrid Elsenbruch; Julia Koelzer; Andreas Rueffer; Andreas Michalsen; Gustav J Dobos
Journal:  Am J Gastroenterol       Date:  2007-10-04       Impact factor: 10.864

6.  Efficacy of mesalazine in the treatment of symptomatic diverticular disease.

Authors:  Francesco Di Mario; Giovanni Aragona; Gioacchino Leandro; Giuseppe Comparato; Libera Fanigliulo; Lucas G Cavallaro; Giulia M Cavestro; Veronica Iori; Marta Maino; Alì M Moussa; Alessandro Gnocchi; Giancarlo Mazzocchi; Angelo Franzé
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

Review 7.  New physiopathological and therapeutic approaches to diverticular disease of the colon.

Authors:  Antonio Tursi
Journal:  Expert Opin Pharmacother       Date:  2007-02       Impact factor: 3.889

Review 8.  Acute diverticulitis of the colon--current medical therapeutic management.

Authors:  Antonio Tursi
Journal:  Expert Opin Pharmacother       Date:  2004-01       Impact factor: 3.889

9.  Assessment and grading of mucosal inflammation in colonic diverticular disease.

Authors:  Antonio Tursi; Giovanni Brandimarte; Walter Elisei; Gian Marco Giorgetti; Cosimo Damiano Inchingolo; Silvio Danese; Fabio Aiello
Journal:  J Clin Gastroenterol       Date:  2008-07       Impact factor: 3.062

10.  The natural history of diverticulitis: fact and theory.

Authors:  Martin H Floch; Iona Bina
Journal:  J Clin Gastroenterol       Date:  2004 May-Jun       Impact factor: 3.062

View more
  31 in total

1.  Uncomplicated diverticulitis, more complicated than we thought.

Authors:  Sarah Y Boostrom; Bruce G Wolff; Robert R Cima; Amit Merchea; Eric J Dozois; David W Larson
Journal:  J Gastrointest Surg       Date:  2012-06-13       Impact factor: 3.452

2.  Diverticular disease: what is the best long-term treatment?

Authors:  Antonio Tursi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-02       Impact factor: 46.802

3.  Symptoms in patients with diverticular disease should not be labelled as IBS.

Authors:  Charlotte Louise Kvasnovsky; Savvas Papagrigoriadis
Journal:  Int J Colorectal Dis       Date:  2014-12-10       Impact factor: 2.571

4.  Diverticular disease of the colon and irritable bowel syndrome: it is time to differentiate.

Authors:  Antonio Tursi
Journal:  Am J Gastroenterol       Date:  2015-05       Impact factor: 10.864

Review 5.  Advances in the management of colonic diverticulitis.

Authors:  Antonio Tursi
Journal:  CMAJ       Date:  2012-08-27       Impact factor: 8.262

Review 6.  Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease.

Authors:  Anastassios C Manolakis; Andreas N Kapsoritakis; Elisavet K Tiaka; Spyros P Potamianos
Journal:  Dig Dis Sci       Date:  2011-01-04       Impact factor: 3.199

Review 7.  Diverticulosis today: unfashionable and still under-researched.

Authors:  Antonio Tursi
Journal:  Therap Adv Gastroenterol       Date:  2016-03       Impact factor: 4.409

Review 8.  Fecal calprotectin use in inflammatory bowel disease and beyond: A mini-review.

Authors:  Bashaar Alibrahim; Mohammed I Aljasser; Baljinder Salh
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04

9.  Increased faecal calprotectin predicts recurrence of colonic diverticulitis.

Authors:  Antonio Tursi; Walter Elisei; Marcello Picchio; Giovanni Brandimarte
Journal:  Int J Colorectal Dis       Date:  2014-05-07       Impact factor: 2.571

10.  Sigmoid diverticulitis in young patients--a more aggressive disease than in older patients?

Authors:  Jörg-Peter Ritz; Kai S Lehmann; Andrea Stroux; Heinz J Buhr; Christoph Holmer
Journal:  J Gastrointest Surg       Date:  2011-02-12       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.